DTS-201

DTS-201 (CPI-0004) is a peptidic prodrug of Doxorubicin (HY-15142A) . DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer[1].

Product Specifications

CAS Number

[274912-87-7]

UNSPSC

12352005

Target

Aminopeptidase; Peptide-Drug Conjugates (PDCs)

Related Pathways

Antibody-drug Conjugate/ADC Related; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

OC(CCC(NCCC(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CC(C)C)C(N[C@H]([C@H](O)[C@H](C)O1)C[C@]1([H])O[C@@H]2C3=C(C[C@](C(CO)=O)(O)C2)C(O)=C4C(C(C5=C(OC)C=CC=C5C4=O)=O)=C3O)=O)=O)=O)=O)=O)=O

Molecular Formula

C49H65N5O18

Molecular Weight

1012.06

References & Citations

[1]Ravel D, et al. Preclinical toxicity, toxicokinetics, and antitumoral efficacy studies of DTS-201, a tumor-selective peptidic prodrug of doxorubicin. Clinical cancer research : an official journal of the American Association for Cancer Research. 2008, 14 (4), 1258–1265.